2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 热门AI工具： |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文摘要生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Future Oncology FUTURE ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 6.6
52人评分
我要评分
声誉 7.6 影响力 5.2 速度 9.1 | |||||||||||||||||||||
| 期刊ISSN | 1479-6694 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1744-8301 | |||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：3.18 | |||||||||||||||||||||
| 2025-2026自引率 | 0.0%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 3.104数据由网友[tall_rose_115]收集提供 | |||||||||||||||||||||
| h-index | 60 | |||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://www.futuremedicine.com/loi/fon | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | http://www.futuremedicine.com/page/submitarticle | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China Author: Wang, Zhiqiang; Zhong, Haijun; He, Yifu; Zhang, Chen; Niu, Zuoxing; Yang, Shujun; Zhang, Tao; Zhu, Liangjun; Shu, Yongqian; Peng, Jianjun; Song, Yan; Li, Jian; Yuan, Ying; Zhang, Haibo; Yu, Gengsheng; Hua, Yunqi; Xiao, Jianjun; Fu, Jianfei; Zheng, Yulong; Zhu, Jingyu; Xue, Hua; Luo, Xian; Su, Weiguo; Qin, Shukui; Li, Jin Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 13, pp. 1561-1571. DOI: 10.1080/14796694.2026.2677771 The early changed rate of sTg to TSH ratio had superior predictive value in evaluating long-term prognosis for pulmonary metastatistic differentiated thyroid carcinoma Author: Li, Jiao; Zhang, Yingying; Wang, Congcong; Lu, Chenghui; Han, Na; Wang, Guoqiang; Jia, Qiang; Tan, Jian; Wang, Xufu; Meng, Zhaowei Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 12, pp. 1409-1420. DOI: 10.1080/14796694.2026.2662500 Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols Author: Shore, Neal D.; Fizazi, Karim; Schweizer, Michael Thomas; Castro, Elena; Azad, Arun A.; George, Daniel J.; da Trindade, Karine Martins; Zeng, Hao; Shrivastava, Nitin; Tonkovyd, Svitlana; Bock, Amy; Nekkalapudi, Srilakshmi; Tang, Yiyun; Lin, Stella; Agarwal, Neeraj Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 12, pp. 1397-1408. DOI: 10.1080/14796694.2026.2667441 TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma Author: Galsky, Matthew D.; Drakaki, Alexandra; Basu, Arnab; McGregor, Bradley; Bedke, Jens; Loriot, Yohann; Kikuchi, Eiji; Guo, Jun; Garmezy, Benjamin; Sridhar, Srikala S.; Singh, Parminder; Koshkin, Vadim S.; Fleming, Mark; Klauss, Gunnar; Lin, Daisy; Liu, Chelsea; Apolo, Andrea B.; Powles, Thomas Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 12, pp. 1387-1396. DOI: 10.1080/14796694.2026.2663956 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Future Oncology的语言要求，还能让Future Oncology编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Future Oncology编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢（1篇） 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB | |||||||||||||||||||||
| 出版商 | Future Medicine Ltd. | |||||||||||||||||||||
| 涉及的研究方向 | ONCOLOGY- | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 2005 | |||||||||||||||||||||
| 年文章数 | 290点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 23.77% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 79.31% | |||||||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | 注册或登录后，查看WOS分区等级 | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1479-6694%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 偏慢,4-8周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Future Oncology顺利发表。
快看看作者怎么说吧：服务好评 论文致谢（1篇） 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China Author: Wang, Zhiqiang; Zhong, Haijun; He, Yifu; Zhang, Chen; Niu, Zuoxing; Yang, Shujun; Zhang, Tao; Zhu, Liangjun; Shu, Yongqian; Peng, Jianjun; Song, Yan; Li, Jian; Yuan, Ying; Zhang, Haibo; Yu, Gengsheng; Hua, Yunqi; Xiao, Jianjun; Fu, Jianfei; Zheng, Yulong; Zhu, Jingyu; Xue, Hua; Luo, Xian; Su, Weiguo; Qin, Shukui; Li, Jin Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 13, pp. 1561-1571. DOI: 10.1080/14796694.2026.2677771 PubMed DOI |
| 2. | The early changed rate of sTg to TSH ratio had superior predictive value in evaluating long-term prognosis for pulmonary metastatistic differentiated thyroid carcinoma Author: Li, Jiao; Zhang, Yingying; Wang, Congcong; Lu, Chenghui; Han, Na; Wang, Guoqiang; Jia, Qiang; Tan, Jian; Wang, Xufu; Meng, Zhaowei Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 12, pp. 1409-1420. DOI: 10.1080/14796694.2026.2662500 PubMed DOI |
| 3. | Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols Author: Shore, Neal D.; Fizazi, Karim; Schweizer, Michael Thomas; Castro, Elena; Azad, Arun A.; George, Daniel J.; da Trindade, Karine Martins; Zeng, Hao; Shrivastava, Nitin; Tonkovyd, Svitlana; Bock, Amy; Nekkalapudi, Srilakshmi; Tang, Yiyun; Lin, Stella; Agarwal, Neeraj Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 12, pp. 1397-1408. DOI: 10.1080/14796694.2026.2667441 PubMed DOI |
| 4. | TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma Author: Galsky, Matthew D.; Drakaki, Alexandra; Basu, Arnab; McGregor, Bradley; Bedke, Jens; Loriot, Yohann; Kikuchi, Eiji; Guo, Jun; Garmezy, Benjamin; Sridhar, Srikala S.; Singh, Parminder; Koshkin, Vadim S.; Fleming, Mark; Klauss, Gunnar; Lin, Daisy; Liu, Chelsea; Apolo, Andrea B.; Powles, Thomas Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 12, pp. 1387-1396. DOI: 10.1080/14796694.2026.2663956 PubMed DOI |
| 5. | Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study Author: Wu, Di; Murali, Bhavna; Clark, Otavio; Luan, Luan; Hlavacek, Patrick; Chaudhary, Mohammed Ashraf; Aydin, Didem; DiBonaventura, Marco Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 10, pp. 1213-1219. DOI: 10.1080/14796694.2026.2656394 PubMed DOI |
| 6. | SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC Author: Peters, Solange; Hochmair, Maximilian; Arbour, Kathryn C.; Rodriguez, Luis Paz-Ares; Reck, Martin; Leal, Ticiana; R. Lindsay, Colin; Shun, Lu; William, William Nassib; Spira, Alexander I.; Sabari, Joshua K.; Henning Grønberg, Bjørn; Nishio, Makoto; Burns, Timothy F.; Girard, Nicolas; Capuzzo, Frederico; Merced, Alyson; Fasnacht, Nicolas; Visseren-Grul, Carla; Negrao, Marcelo V Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 9, pp. 1073-1082. DOI: 10.1080/14796694.2026.2651961 PubMed DOI |
| 7. | Comparison of concurrent chemoradiotherapy followed by immunotherapy and induction chemoimmunotherapy followed by radiotherapy in unresectable stage III NSCLC: a retrospective cohort study Author: Xu, Qinhao; Qi, Yana; Zhai, Xiaoyang; Chen, Feihu; Guo, Yingfan; Zhu, Hui Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 819-829. DOI: 10.1080/14796694.2026.2637732 PubMed DOI |
| 8. | Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs Author: Yu, Evan Y.; Gratzke, Christian; Burotto, Mauricio; Zhang, Alison Y.; Levesque, Eric; Ortega, Francisco; Peer, Avivit; Vile, Donald; Chen, Zheng Hong; Song, Yue; Schloss, Charles; Todoric, Jelena; Garratt, Chris; Poehlein, Christian; Antonarakis, Emmanuel S.; Fizazi, Karim Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 765-772. DOI: 10.1080/14796694.2025.2595914 PubMed DOI |
| 9. | Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors Author: Schram, Alison M.; Park, John J.; Italiano, Antoine; Kitano, Shigehisa; Guo, Ye; Li, Jin; Bedard, Philippe L.; van Marcke, Cedric; Ko, Ryo; Lunger, Lukas; Klotz, Daniel M.; Hussain, Jo; Maier, Daniela; Erzen, Damijan; Planchard, David; Prenen, Hans; Clay, Timothy D.; Park, Joon O.; Kim, Hyung-Don; Hernando-Calvo, Alberto; Maruki, Yuta; Ponz-Sarvise, Mariano; Dumbrava, Ecaterina Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 795-803. DOI: 10.1080/14796694.2026.2637740 PubMed DOI |
| 10. | Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial Author: Hao, Shengnan; Wang, Xiaomin; Ding, Huiping; Chen, Yun; Liu, Qi; Zhang, Junhua; Fan, Xingwen; Wu, Zhenhua; Lin, Ying; Xu, Xiaofang; Mao, Guangmin; Ai, Dashan; Deng, Jiaying; Zhu, Hongcheng; Ye, Jinjun; Mo, Miao; Hu, Zhihuang; Wang, Huijie; Cheng, Wenwu; Feng, Wei; Ling, Yiqun; Xu, Yufen; Du, Shisuo; Wang, Jialei; Zhao, Kuaile Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 773-780. DOI: 10.1080/14796694.2026.2637738 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共173条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
